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Abstract
Background: Inflammation is a key contributor to central nervous system (CNS) injury such as stroke, and is a
major target for therapeutic intervention. Effective treatments for CNS injuries are limited and applicable to only a
minority of patients. Stem cell-based therapies are increasingly considered for the treatment of CNS disease,
because they can be used as in-situ regulators of inflammation, and improve tissue repair and recovery. One
promising option is the use of bone marrow-derived mesenchymal stem cells (MSCs), which can secrete anti-
inflammatory and trophic factors, can migrate towards inflamed and injured sites or can be implanted locally. Here
we tested the hypothesis that pre-treatment with inflammatory cytokines can prime MSCs towards an anti-
inflammatory and pro-trophic phenotype in vitro.
Methods: Human MSCs from three different donors were cultured in vitro and treated with inflammatory
mediators as follows: interleukin (IL)-1α, IL-1β, tumour necrosis factor alpha (TNF-α) or interferon-γ. After 24 h of
treatment, cell supernatants were analysed by ELISA for expression of granulocyte-colony stimulating factor (G-CSF),
IL-10, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), IL-1 receptor antagonist (IL-1Ra) and
vascular endothelial growth factor (VEGF). To confirm the anti-inflammatory potential of MSCs, immortalised mouse
microglial BV2 cells were treated with bacterial lipopolysaccharide (LPS) and exposed to conditioned media (CM) of
naïve or IL-1-primed MSCs, and levels of secreted microglial-derived inflammatory mediators including TNF-α, IL-10,
G-CSF and IL-6 were measured by ELISA.
Results: Unstimulated MSCs constitutively expressed anti-inflammatory cytokines and trophic factors (IL-10, VEGF,
BDNF, G-CSF, NGF and IL-1Ra). MSCs primed with IL-1α or IL-1β showed increased secretion of G-CSF, which was
blocked by IL-1Ra. Furthermore, LPS-treated BV2 cells secreted less inflammatory and apoptotic markers, and
showed increased secretion of the anti-inflammatory IL-10 in response to treatment with CM of IL-1-primed MSCs
compared with CM of unprimed MSCs.
Conclusions: Our results demonstrate that priming MSCs with IL-1 increases expression of trophic factor G-CSF
through an IL-1 receptor type 1 (IL-1R1) mechanism, and induces a reduction in the secretion of inflammatory
mediators in LPS-activated microglial cells. The results therefore support the potential use of preconditioning
treatments of stem cells in future therapies.
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Background
Stem cells are undifferentiated cells found in many adult
tissues, the function of which is renewal of damaged tis-
sues during ageing or after disease and injuries. Because
of their regenerative properties, these cells are being in-
creasingly considered as new therapeutic agents for the
treatment of central nervous system (CNS) diseases.
Mesenchymal stem (or stromal) cells (MSCs) are one
type of multipotent stem cells that can be isolated and
cultured from several tissues [1, 2] and differentiated
into several cell lineages [3, 4]. MSCs sense signals from
tumours [5] and injured, inflamed or ischemic tissues
[6], migrate towards those sites and are even able to
cross the blood–brain barrier [7]. Once infiltrated into
the brain, MSCs produce an array of mediators such as
cytokines and growth factors [8, 9] that promote tissue
repair mainly by activating endogenous repair mecha-
nisms [10, 11], and by acting as temporal immune-
suppressants [1, 6]. These properties make MSCs ideal
candidates for cell-based therapies, particularly for the
treatment of CNS disorders such as stroke, Huntington’s
disease, amyotrophic lateral sclerosis or Parkinson’s dis-
ease [12]. The safety and efficacy of MSCs have already
been demonstrated mostly in pre-clinical models of is-
chaemic stroke [2, 9, 13], intracerebral haemorrhage
[14], amyotrophic lateral sclerosis [15] and Alzheimer’s
disease [16]. However, the precise mechanisms by which
MSCs exert beneficial effects remain elusive [17].
A process implicated in the pathogenesis of CNS dis-
orders is inflammation, a key host defence response to
infection and injury. Inflammation is known to contrib-
ute to neuronal injury [18], but is also implicated in re-
pair mechanisms in the brain [19]. Achieving the right
balance between the damaging and reparative role of in-
flammation is considered a major target for therapeutic
intervention [20]. Although some anti-inflammatory
treatments are in clinical trial for acute brain injury,
current effective treatments are limited [21, 22]. Finding
new therapies with longer time windows and wider
therapeutic effects has become a priority. Inflammation
in the brain is critically regulated by inflammatory cyto-
kines such as interleukin (IL)-1 and tumour necrosis fac-
tor alpha (TNF-α) that are expressed by, and act on,
microglia, astrocytes and endothelial cells [23]. Studies
using MSCs delivered to the brain have been carried out
[24, 25], but no studies have yet assessed the effect of
the inflammatory environment on the secretory profile
of these locally delivered MSCs.
The MSC secretome can be modulated to boost the
beneficial actions of these cells, so that they can respond
even more effectively to inflammatory conditions. One
way to increase this potential is through priming or pre-
conditioning. Inflammatory priming occurs when a mild
(or sub-lethal) inflammatory event induces cellular
changes that drive cells towards a more anti-
inflammatory phenotype, which can eventually lead to a
more effective response against future lethal or severe
inflammatory events. Different preconditioning treat-
ments have been tested in MSCs in order to induce se-
lected phenotypes [26, 27], but the effect of specific
cytokines known to regulate inflammation in the brain
or the secretory profile of MSCs has not been widely
studied. Here, we tested the hypothesis that priming
with inflammatory stimuli would modify the secretome
of MSCs towards an anti-inflammatory and trophic
phenotype [28]. We show for the first time that MSCs
express high constitutive levels of key anti-inflammatory
and trophic factors, and that priming with IL-1 triggers
secretion of the trophic factor granulocyte-colony stimu-
lating factor (G-CSF), an effect that was only observed
in response to IL-1. The addition of IL-1-primed MSC
conditioned media (CM) to inflamed microglial cells
caused a reduction in the secretion of inflammation
markers (IL-6, G-CSF and TNF-α), and an increase in
the microglial-derived anti-inflammatory mediator cyto-
kine IL-10. These results highlight the ability of MSCs to
orchestrate other cells to induce a more effective anti-
inflammatory response, demonstrating the potential use
of priming inflammatory treatments to enhance the
beneficial actions of MSCs for future stroke therapies.
Methods
Human MSCs
Human bone marrow-derived MSCs were purchased
from Lonza (UK) and 3H Biomedical (Sweden). Three
different donors were used in this study: donor 1 (Lonza,
38 years old, male), donor 2 (Lonza, 21 years old, fe-
male) and donor 3 (3H Biomedical, 22 weeks old, fetal).
Culture flasks (Corning, UK) were coated with 0.1% gel-
atin in PBS, overnight at 37 °C, and washed with PBS.
MSCs were subsequently cultured in MesenPRO RS
medium (Invitrogen, UK) supplemented with 1% penicil-
lin/streptomycin and 2 mM glutamine. The medium was
changed every 4–5 days until cells reached 70–80%
confluency. Cells were then detached with 0.5% trypsin–
EDTA (Sigma-Aldrich, UK), counted and split into dif-
ferent tissue culture flasks and further cultured as
already described. Cells used for experiments were ob-
tained from culture passages 4–6 and were seeded in
gelatin-coated plates at 13,000 cells/cm2, 24 h prior to
treatment.
Differentiation of MSCs and flow cytometry
Cells obtained from different donors were tested for
their ability to differentiate into osteocytes or adipocytes
using commercial kits (Millipore, UK), according to the
manufacturer’s instructions. MSCs were further charac-
terised phenotypically by multicolour flow cytometry
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using the BD Stemflow™ hMSC Analysis Kit (BD Biosci-
ences, UK) on a FACSVerse flow cytometer (BD Biosci-
ences, UK). The surface markers used for the phenotypic
characterisation of MSCs were CD73, CD90, CD105,
CD34, CD11b, CD19, CD45 and HLA-DR, as stated by
the International Society for Cellular Therapy [29].
Microglial cells (BV2 cells)
BV2 cells (ATCC, UK), an immortalised murine microglial
cell line, were cultured in RPMI-1640 medium
(Sigma-Aldrich, UK) supplemented with 10% FBS
(Gibco, UK) and 1% penicillin/streptomycin (Sigma-
Aldrich, UK) until 70–80% confluent. Cells were de-
tached with trypsin–EDTA (Sigma-Aldrich, UK),
counted and seeded at a density of 13,000 cells/cm2.
Cell treatments
MSC priming
MSC cultures were treated with recombinant human
IL-1α, IL-1β, TNF-α or interferon gamma (IFN-γ) (all
from R&D Systems UK) at a final, concentration of 1,
10, 50 or 100 ng/ml. After 24 h of treatment, culture
supernatants were collected and analysed for the
presence of several cytokines (see “Enzyme-linked im-
munosorbent assay”).
Blocking IL-1 receptor antagonist experiments
IL-1 receptor antagonist (IL-1Ra) (200 μg/ml, Kineret®;
Biovitrum, Sweden) was added to MSCs. After 10 min,
priming treatments were added normally, without wash-
ing (final concentration of 100 μg/ml for IL-1Ra and
10 ng/ml for inflammatory cytokines). After 24 h, super-
natants were collected and analysed.
Conditioned medium treatment of BV2 cells
MSCs were seeded at a density of 13,000 cells/cm2 in
24-well plates (Corning, UK). Once attached, cells were
primed with 10 ng/ml of human recombinant IL-1α
(R&D Systems, UK) for 5 min. MSCs were then washed
twice with PBS, and fresh MesenPRO medium was
added. After 24 h of incubation, CM were collected.
BV2 cells were simultaneously treated with CM and
1 μg/ml lipopolysaccharide (LPS) from E. coli 0127:B8
(Sigma-Aldrich, UK). Supernatants were collected at
24 h—see detailed experimental protocol (Fig. 1).
Fig. 1 Experimental protocol of MSC-CM treatment on BV2 cells. MSCs were primed with IL-1α, and the CM used on BV2 cells (treated or not with
LPS). Summary of experimental conditions: 1, MSC-CM; 2, primed MSC-CM; 3, untreated BV2; 4, BV2 treated with LPS; 5, BV2 treated with MSC-CM; 6,
BV2 treated with primed MSC-CM; 7, BV2 treated with LPS and MSC-CM; 8, BV2 treated with LPS and primed MSC-CM. hMSC human mesenchymal
stem/stromal cell, IL interleukin, LPS lipopolysaccharide
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Blocking human G-CSF experiments
CM from MSCs (primed and unprimed) were incubated
in plates previously coated with a neutralising antibody
against human G-CSF (R&D systems, UK). After 2 h of
incubation at RT and sterile conditions, CM were col-
lected and added to BV2 cells as already described, and
cytokines were measured.
Lactate dehydrogenase assay
Cell death and proliferation of BV2 cells after cyto-
kine treatments were analysed using a lactate de-
hydrogenase (LDH) assay kit (Promega, UK)
according to the manufacturer’s instructions. In brief,
to assess cell death, supernatants were collected, LDH
was measured and optical densities were normalised
to 100% cell death control. To assess proliferation, all
cells were lysed and measured LDH concentrations
were compared with control values (untreated BV2
cells). An increase in LDH measurements was inter-
preted as an increase in cell death or proliferation
(respectively).
Enzyme-linked immunosorbent assay
Levels of human IL-10, brain-derived neurotrophic
factor (BDNF), nerve growth factor (NGF), vascular
endothelial growth factor (VEGF), TNF-α and G-CSF
in culture media from MSCs were quantified by
ELISA using DuoSet® kits (R&D Systems, UK) accord-
ing to the manufacturer’s instructions. Human IL-1Ra
levels were measured using an ELISA kit from Pepro-
tech (UK) combined with external standards prepared
using recombinant human IL-1Ra (National Institute
for Biological Standards and Controls (NIBSC), UK).
Quantification limits in human ELISAs were 10 pg/ml
for IL-1Ra, 15 pg/ml for G-CSF, NGF, TNF-α and
VEFG, and 25 pg/ml for BDNF and IL-10. ELISA kits
for mouse IL-6, TNF-α, IL-10 and G-CSF (all quanti-
fication limits ~30 pg/ml) were purchased from R&D
Systems and used following the manufacturer’s in-
structions. For each assay, samples were diluted as
needed and protein levels were calculated against a
four-parameter logistic (4-PL) curve fit. All values are
expressed as mean ± standard error of the mean
(SEM).
Statistical analysis
In each experiment, a minimum of four independent
cultures were included. Graphs, 4-PL curves and stat-
istical analysis were done using GraphPad Prism soft-
ware version 7 for Windows (CA, USA). Treatment
effects in each donor were assessed by non-
parametric one-way ANOVA analysis. BV2 data were
analysed by parametric one-way ANOVA. Fisher post-
hoc tests were only performed if statistical signifi-
cance was achieved (p < 0.05).
Results
Phenotypic characterisation of human MSCs in vitro
MSCs derived from three donors were differentiated
successfully into adipocytes and osteocytes, evidenced
by the presence of lipid droplets (stained in red,
Fig. 2a) and calcium deposits (Fig. 2b), respectively.
Different antibodies and corresponding isotype con-
trols were used to assess expression of specific MSC-
positive cell surface markers [29]. MSCs derived from
different donors were, on average, 98.65% CD90-
positive (Fig. 2c), 98.17% CD73-positive (Fig. 2d) and
91.50% CD105-positive (Fig. 2e). Less than 2% of the
cells were positive for CD34, CD11b, CD45, CD19
and HLA-DR (Fig. 2f, Table 1). FACS analysis also in-
dicated the presence of single-cell populations, with a
low amount of debris, duplets and triplets, indicating
a high proportion of normal and healthy cells (data
not shown).
Fig. 2 Characterisation of MSCs. Details of MSCs differentiated into
adipocytes (a) and osteocytes (b). Scale bar: 25 μm (a) and 200 μm
(b). Flow cytometry graphs showing the presence of CD90 (c), CD73
(d) and CD105 (e), and the absence of markers from other cell types
(f). Percentages represent the average of all donors. Flow cytometry
graphs were obtained from donor 3, and are representative of
all donors
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MSCs secrete basal levels of anti-inflammatory and
neurotrophic mediators
MSCs obtained from different donors were expanded
and cultured, and their media were analysed for the
presence of anti-inflammatory cytokines and trophic fac-
tors under basal conditions by ELISA (all values pre-
sented are expressed as mean ± SEM). MSCs
constitutively expressed BDNF, IL-1Ra, NGF, VEGF, G-
CSF and IL-10 (Fig. 3), although the levels secreted var-
ied between donors; MSCs from donors 1 and 3 secreted
moderate concentrations of BDNF (66.5 ± 3.6 pg/ml and
62.6 ± 4.7 pg/ml, respectively), while donor 2 only se-
creted 6.2 ± 0.9 pg/ml BDNF (Fig. 3a). In contrast, cells
from donor 2 secreted the highest concentration of NGF
(11.0 ± 7.1 pg/ml) (1.2 ± 1.0 pg/ml in donor 1 and 3.4 ±
4.0 pg/ml in donor 3; Fig. 3b).
Concentrations of G-CSF were also variable between
donors, with low levels secreted in all donors (not de-
tectable in donor 1, 38.3 ± 7.9 pg/ml in donor 2 and 6.7
± 4.7 pg/ml in donor 3; Fig. 3c). The levels of IL-10
(Fig. 3d) were similar in all three donors (13.9 ± 11.1 pg/
ml, 14.1 ± 11.5 pg/ml and 15.7 ± 9.7 pg/ml, respectively).
Other factors such as VEGF were secreted in high
amounts in cells from donor 1 (1182.3 ± 128.5 pg/ml);
levels were lower in the other donors (donor 2, 159.3 ±
17.7 pg/ml and donor 3, 247.0 ± 55.6 pg/ml; Fig. 3e).
The protein with the highest secretion in all three do-
nors was IL-1Ra, which was in the nanogram range
(0.79 ± 0.1 ng/ml in donor 1, 2.4 ± 0.4 ng/ml in donor 2),
being especially high in the youngest donor (donor 3,
22.4 ± 4.9 ng/ml; Fig. 3f ).
IL-1 selectively primes MSCs to produce high levels of
anti-inflammatory and pro-trophic factors
Basal concentrations of mediators were assessed in the
supernatant of MSCs treated with increasing concentra-
tions of IL-1α, IL-1β, TNF-α or IFN-γ for 24 h. Whilst
TNF-α or IFN-γ had no effect on secretion of G-CSF
from MSCs derived from the three donors (Fig. 4a, b),
IL-1α and IL-1β induced strong G-CSF release from
MSCs obtained from all of the donors (Fig. 4c, d). The
magnitude of this response was different in each donor,
with the highest increase observed in MSCs obtained
from donor 3 (ranging from 5.9 ± 3.6 pg/ml in basal con-
ditions to 6.8 ± 1.7 ng/ml after IL-1α and 7.4 ± 2.1 ng/ml
after IL-1β). In contrast, IL-1α and IL-1β had no effect
on VEGF, NGF or IL-1Ra expression (Additional file 1:
Figure S1). Increased IL-10 levels were observed after
IL-1α and IL-1β treatments, although this was not sig-
nificant due to high variability. BDNF levels in response
to IL-1α and IL-1β were highly variable with cells from
Table 1 Phenotyping characterisation of MSCs for all markers
and all donors
Donor 1 Donor 2 Donor 3 Mean ± SEM
CD90 95.97 100 100 98.65 ± 1.10
CD73 94.76 99.91 99.86 98.17 ± 1.39
CD105 80.24 99.48 94.79 91.50 ± 4.73
Other 3.23 2.07 0.21 1.83 ± 0.72
Quantification of marker expression from three independent cultures,
expressed as the mean ± SEM
MSC human mesenchymal stem/stromal cell
Fig. 3 Constitutive secretion. MSCs express several anti-inflammatory cytokines and trophic factors under basal conditions (n = 3 experiments/
donor), as measured by ELISA. Measurements of BDNF (a), NGF (b), G-CSF (c), IL-10 (d), VEGF (e) and IL-1Ra (f) in MSCs derived from the three different
donors. BDNF brain-derived neurotrophic factor, G-CSF granulocyte-colony stimulating factor, IL interleukin, IL-1Ra interleukin-1 receptor antagonist, nd
not detectable, NGF nerve growth factor, VEGF vascular endothelial growth factor
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the three donors showing increased, decreased or un-
altered BDNF levels after IL-1α and IL-1β treatments
(Additional file 1: Figure S1). Finally, release of VEGF,
NGF, IL-1Ra, IL-10 and BDNF was unaltered by treat-
ments with TNF-α or IFN-γ (Additional file 2: Figure S2,
only a significant decrease in VEGF was detected in
donor 1). Because cells from donor 3 produced the high-
est basal level of IL-1Ra and showed the most robust in-
crease in the secretion of G-CSF in response to IL-1, all
further experiments were carried out using cells from
this donor.
IL-1 acts normally through IL-1 receptor type 1
(IL-1R1) [30]. To assess whether the actions of IL-1
on MSCs occurred via actions on IL-1R1, we tested
the effect of human recombinant IL-1Ra (added prior
to treatment with IL-1) on G-CSF release from IL-1-
primed MSCs. IL-1Ra added before treatment with
IL-1α or IL-1β significantly and completely blocked
the priming effect of IL-1 on G-CSF secretion (p <
0.01–0.001; Fig. 4e, f ), thus confirming that IL-1 ac-
tions were mediated by IL-1R1 activity.
Anti-inflammatory effect of conditioned medium of MSCs
on LPS-treated microglial cells is potentiated by priming
of MSCs with IL-1
To test the hypothesis that MSCs can exert anti-
inflammatory properties and could therefore be used as
potent anti-inflammatory agents, we added CM from
untreated or IL-1-primed MSCs to LPS-treated BV2
cells. After priming with IL-1α (see scheme in Fig. 1),
MSCs exhibited increased secretion of IL-6 (p < 0.01;
Fig. 5a) and G-CSF (Fig. 5c), whilst TNF-α and IL-10
remained undetectable (Fig. 5b, d). Stimulation of BV2
cells with LPS induced microglial activation, measured by
increased secretion of IL-6 (~170 to ~2000 pg/ml, p <
0.001; Fig. 5e), TNF-α (~1800 pg/ml, p < 0.001; Fig. 5f)
and G-CSF (~10,000 pg/ml, p < 0.001; Fig. 5g).
Fig. 4 Secretion of G-CSF by MSCs. Levels of G-CSF were assayed after treating cells from different donors (n = 3 experiments/donor) with different
concentrations of TNF-α (a) and IFN-γ (b) for 24 h, which had no significant effect on the secretion of G-CSF. Treatments with IL-1α (c) and IL-1β (d) for
24 h induced a strong increase in the secretion of G-CSF. The youngest donor presented the highest increase in secretion, as measured by ELISA (*p <
0.05, **p < 0.01, ***p < 0.001 vs untreated from same donor), despite all donors showing an increase in the secreted levels of G-CSF. The increased
secretion of G-CSF in response to priming with IL-1α (e) and IL-1β (f) is completely inhibited when IL1-Ra (100 μg/ml) is added 10 min
prior to the treatment. *p < 0.05, ***p < 0.001 vs untreated; ++p < 0.05, +++p < 0.001 IL-1Ra condition vs cytokine treatment only. Cells from
donor 3 were used in the inhibition experiment. G-CSF granulocyte-colony stimulating factor, IFN-γ interferon gamma, IL interleukin, IL-1Ra
interleukin-1 receptor antagonist, nd not detectable, TNF-α tumour necrosis factor alpha
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The addition of MSC-CM to LPS-treated BV2 micro-
glial cells did not alter the secretion of IL-6 (Fig. 5e), but
induced a significant reduction in TNF-α (~-25%, p <
0.01) and G-CSF (~55% reduction, p < 0.001), as well as
a marked increase in secreted IL-10 (12-fold increase,
from ~2 to ~24 pg/ml). These changes were more pro-
nounced when LPS-treated BV2 cells were exposed to
CM from IL-1α-primed MSCs, as shown by a significant
reduction in IL-6 secretion (~-35%, p < 0.001 vs LPS, p <
0.0001 vs untreated CM; Fig. 5e) and in TNF-α (–41%,
p < 0.001 vs LPS, p < 0.05 vs untreated CM; Fig. 5f ) and
a greater increase in IL-10 secretion (13-fold increase,
~30 pg/ml, vs untreated CM; Fig. 5h). The reduction in
the secretion of G-CSF was unaffected by priming of
MSCs with IL-1α (~55% reduction, p < 0.001 vs LPS
treated BV2; Fig. 5g). CM from MSCs primed with
TNF-α and IFN-γ were not effective at reducing the
secretion of inflammatory markers (data not shown).
CM (from untreated or primed MSCs) added to un-
treated BV2 cells had no effect on any of the media-
tors tested, thus discarding an unspecific effect of the
addition of media from a different cell type. We mea-
sured both human and mouse isoforms of these me-
diators in supernatants from all conditions, and no
cross-reactivity between species was observed. Finally,
none of the treatments induced significant cell death
or proliferation in BV2 microglial cultures (Additional
file 3: Figure S3).
Fig. 5 BV2 cell treatment with MSC-CM. Concentrations of human IL-6 (a, **p < 0.01 primed vs unprimed), TNF-α (b), G-CSF (c) and IL-10 (d) were
measured in the CM of MSCs (n= 4 experiments). ELISAs to detect mouse isoforms of the same molecules (e, f, g, and h, respectively, n= 4 experiments)
showed that the addition of MSC-CM induced significant changes in their secretion (when compared with LPS-treated BV2 cells). CM from IL-1α-primed
MSCs induced a stronger response, evidenced by a larger reduction in the secretion of IL-6 (p< 0.001) and TNF-α (p< 0.05) and by an increased secretion
of IL-10. Note that most IL-10 values are below the quantification limit of the assay (dashed line), so statistical analysis cannot be performed with these
values. *p< 0.05, **p < 0.01, ***p< 0.001, ****p < 0.001. G-CSF granulocyte-colony stimulating factor, hMSC human mesenchymal stem/stromal cell, IFN-γ
interferon gamma, IL interleukin, IL-1Ra interleukin-1 receptor antagonist, LPS lipopolysaccharide, nd not detectable, TNF-α tumour necrosis factor alpha
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Given the large amount of G-CSF secreted by MSCs
in response to IL-1 preconditioning, and the fact the
anti-inflammatory effect of MSC-CM was significantly
enhanced by IL-1 priming, we next hypothesised that G-
CSF could be a key mediator involved in these anti-
inflammatory actions. To this end, we found that the
levels of mouse IL-6 and TNF-α were significantly
higher when human G-CSF was neutralised with a spe-
cific antibody (Fig. 6), thus confirming its role in the
modulation of the secretion of these two molecules for
anti-inflammatory actions on BV2 cells.
Discussion
We describe the priming of MSCs with inflammatory cy-
tokines to test whether this causes a secretory profile to-
wards an anti-inflammatory and pro-trophic phenotype.
We show that treatment of MSCs with IL-1α or IL-1β
increased the secretion of trophic factors such as G-CSF.
This was a specific effect of IL-1, because TNF-α and
IFN-γ failed to induce this response.
In order to test the cells’ anti-inflammatory and pro-
trophic potential, we added CM from MSCs to inflamed
murine BV2 cells. Priming of MSCs induced the secre-
tion of anti-inflammatory mediators such as IL-10 in
BV2 cells, as well as a decrease in the secretion of pro-
inflammatory cytokines (IL-6, TNF-α). These effects
were more marked when MSCs had been primed previ-
ously with IL-1, supporting the potential use of priming
treatments to induce more desirable phenotypes. We
also confirmed that IL-1 exerts these effects via IL-1R1,
because IL-1Ra completely blocked the increase in G-CSF
after the priming. Furthermore, inhibition experiments
using a specific human G-CSF neutralising antibody dem-
onstrated that G-CSF is critical for the anti-inflammatory
effect of MSCs triggered by IL-1 priming.
While first identified as a growth factor that promotes
survival, proliferation and differentiation of myeloid pro-
genitors [31], G-CSF has since been found to be a key
neurotrophic factor in the CNS [32]. The G-CSF recep-
tor is expressed throughout the adult CNS and its acti-
vation includes inhibition of apoptosis in neurons and
initiation of neurogenesis in neural stem cells [33, 34].
Potentially beneficial actions of G-CSF reported in
animal models include increased synaptogenesis,
angiogenesis, neuroprotection, neurogenesis, plasticity
and anti-apoptosis [34, 35]. In rodent models of cere-
bral ischaemia, G-CSF treatment has been shown to have
neuroprotective effects leading to reduced infarct volume
[36, 37], improved functional recovery [34, 38] and neuro-
genesis [39]. G-CSF has also been described as a mobilisa-
tion factor of endogenous or transplanted MSCs [40, 41],
which along with all of the aforementioned features could
explain some sensorimotor and functional improvements
already described with MSC treatment [42, 43]. Moreover,
the increased secretion of G-CSF induced by MSCs
induced an M2 or M2-like functional phenotype in mac-
rophages (which implies an anti-inflammatory and pro-
regenerative phenotype) [44–46], as well as leading to
higher rates of tissue remodelling and angiogenesis [47].
There is some controversy in the literature over the ef-
fects of G-CSF on experimental ischaemic stroke and
brain haemorrhage [48], with positive or neutral out-
comes as well as some negative results being reported
[49, 50]. Clinical trials showed that the administration of
G-CSF to stroke patients is safe (ClinicalTrials.gov
NCT00901381, NCT00132470), but the data on efficacy
have been contradictory [51] (ClinicalTrials.gov
NCT009278361, NCT00132470). A study has suggested
that G-CSF could be more beneficial when administered in
the chronic phase to potentiate neural repair mechanisms
[48]. This potential efficacy in delayed treatments favours
the hypothesis that administration of cell therapies in the
chronic phase leads to remodelling and repair of the injured
brain. Other clinical trials assessing the safety and efficacy
of G-CSF in Alzheimer’s disease (ClinicalTrials.gov
NCT01617577), ALS (ClinicalTrials.gov NCT01825551),
Fig. 6 G-CSF neutralisation of MSC-CM induces raised IL-6 and TNF-α levels in BV2 cells. Addition of MSC-CM depleted of G-CSF induced higher
secretion of IL-6 (a) and TNF-α (b) from LPS-stimulated BV2 cells (p < 0.001 for IL-6; p < 0.0001 and p < 0.01 vs non-neutralised CM, for TNF-α when
CM was from unprimed or primed MSCs, respectively). G-CSF granulocyte-colony stimulating factor, h human, MSC mesenchymal stem/stromal
cell, IL interleukin, LPS lipopolysaccharide, nd not detectable, TNF-α tumour necrosis factor alpha
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brain injury and other neurodegenerative diseases (Clinical-
Trials.gov NCT02236065) are being conducted.
G-CSF may play a dual roleas it can also be produced
as an autocrine protective mechanism, because neurons
secrete it in ischemic conditions in an attempt to reduce
neuronal apoptosis [34, 52]. In this study we have shown
that MSC priming with IL-1 induces increased secretion
of G-CSF (in MSCs), whilst G-CSF secretion is reduced
in LPS-treated BV2 cells exposed to MSC-CM, demon-
strating the dual role of G-CSF. In this case, the reduc-
tion in the secretion of G-CSF by BV2 cells might
indicate that BV2 cells were responding more effectively
to the inflammation.
The increase in IL-10 in BV2 cells after MSC-CM
treatment adds potential to the therapeutic application
of MSCs, because IL-10 is known to inactivate macro-
phages and to trigger matrix deposition and tissue re-
modelling [45, 46]. MSCs can be primed to secrete
trophic factors, and they can also induce changes in the
secretory phenotype of other cells, and could potentially
increase the chances for injured or inflamed tissue to
achieve a better recovery after an inflammatory event. In
agreement with this, our data demonstrated that MSCs
regulate microglial cells to secrete less inflammatory me-
diators and more anti-inflammatory cytokines, which
may contribute to the healing and repair of the tissue.
We also need to consider the constitutive secretion of
a wide variety of other cytokines. MSCs constitutively
secrete high concentrations of IL-1Ra, and this is of
interest because it has been shown in humans that IL-
1Ra is required to be administrated repeatedly and in
high doses to maintain its efficacy [53]. Therefore, MSCs
from certain donors (those with a high constitutive se-
cretion) may become a cellular system to deliver high
and sustained doses of IL-1Ra. Besides, because MSCs
tend to migrate to injured, inflamed or ischaemic areas
[5–7], this would be a targeted delivery. This would
imply a significant improvement from actual therapies,
which require repeated doses of expensive recombinant
human proteins [53, 54]. Other molecules that are
expressed constitutively could possibly be stimulated by
other priming agents not tested here.
Our results highlighted variability between MSCs from
different donors, but a clear correlation between their
secretome and sources (sex and age) was not found.
Similarly to other studies [55, 56], we could not observe
any clear relationship between the levels of these cyto-
kines and the age or the sex of the donor. Variability be-
tween donors has been reported widely in the literature,
and can be observed at the gene expression level [57, 58]
and in response to differentiation stimuli [55, 58, 59].
When describing the secretome of MSCs, results are
highly variable between studies, indicating once more
the important variability of these cells and the existence
of subpopulations [60–62]. This variability needs to be
considered when designing new cell therapies because it
can limit applicability.
Conclusions
Stem cell therapies using MSCs are a promising option for
the treatment of several neurological conditions because
of their safety, their immunosuppressive properties and
their ability to sense and reach the inflamed area, there-
fore potentially improving recovery and repair [1, 2, 6, 10].
In our study, we demonstrate that preconditioning treat-
ments increased MSC secretion of anti-inflammatory me-
diators and trophic factors [8]. They can also trigger
changes in other cells, switching them towards a more
anti-inflammatory and pro-regenerative phenotype. These
results highlight the possibility of modulating the secre-
tome of MSCs, and confirm the beneficial actions they
can exert when added to inflamed cells or tissues. Taken
together, these results propose MSCs as an excellent can-
didate to be considered when designing more effective cell
therapies to be used in CNS inflammatory conditions.
Additional files
Additional file 1: Figure S1. Is showing levels of cytokines secreted by
MSCs from three different donors after IL-1α or IL-1β treatment. Secretion
of VEGF (A, B) and NGF (C, D) was not modified by any treatments in any
of the donors, but secretion of IL-10 showed a non-significant increase in
some donors (E, F). Levels of IL-1Ra were high and unchanged after IL-1
treatments (G, H). Changes in the levels of BDNF were different in each
donor, showing significance in some donors (I, J) (n = 3 experiments/
donor). *p < 0.05, **p < 0.01, ***p < 0.001 vs untreated. (TIF 461 kb)
Additional file 2: Figure S2. Is showing levels of cytokines secreted by
MSCs from three different donors, after TNF-α or IFN-γ treatment. Secretion
of VEGF (A, B), NGF (C, D), IL-10 (E, F), IL-1Ra (G, H) and BDNF (I, J). Donor 1
showed a significant decrease in the amount of VEGF, but donors 2 and 3
showed no response. No significant changes were detected in secretion of
NGF, IL-10, IL-1Ra and BDNF (n = 3 experiments/donor). *p < 0.05, **p < 0.01,
***p < 0.001 vs untreated. (TIF 470 kb)
Additional file 3: Figure S3. Is showing measurement of cell death
and proliferation of BV2 cells in CM treatment experiments. LDH was
measured in supernatants (A) and cell lysates (B) as indirect
measurements of cell death and proliferation. None of the treatments
induced significant cell death or proliferation. (TIF 585 kb)
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